posted on 2020-06-11, 13:56authored byAda AdminAda Admin, Katharina Herzog, Johan Berggren, Mahmoud Al Majdoub, Claudia Balderas Arroyo, Andreas Lindqvist, Jan Hedenbro, Leif Groop, Nils Wierup, Peter Spégel
Bariatric surgery is an efficient method
to induce weight loss and frequently also remission of type 2 diabetes (T2D). Unpaired
studies have shown bariatric surgery and dietary interventions to impact differentially
on multiple hormonal and metabolic parameters, suggesting that bariatric
surgery causes T2D remission at least partially <i>via</i> unique mechanisms.
<p>In the present study, plasma metabolite
profiling was conducted in patients with (n=10) and without T2D (n=9) subjected
to Roux-en-Y gastric bypass surgery (RYGB). Mixed-meal tests were conducted at
baseline, after the pre-surgical very low-calorie diet (VLCD) intervention,
immediately after RYGB, and after a 6-weeks recovery period. Thereby, we could
compare fasted and post-prandial metabolic consequences of RYGB and VLCD in the
same patients.</p>
<p>VLCD yielded a pronounced increase
in fasting acylcarnitine levels, whereas RYGB, both immediately and after a
recovery period, resulted in a smaller, but opposite effect. Furthermore, we
observed profound changes in lipid metabolism following VLCD, but not in response
to RYGB.</p>
<p>Most changes previously associated
with RYGB were found to be consequences of the pre-surgical dietary
intervention. Overall, our results question previous findings of unique
metabolic effects of RYGB and suggest that the effect of RYGB on the metabolite
profile is mainly attributed to caloric restriction.</p>
Funding
This work was supported by the Påhlssons Foundation, the Crafoord Foundation, the Novo Nordisk Foundation, the Swedish Diabetes Foundation, the Hjelt Foundation, the Per and Ulla Schyberg Foundation, the Diabetes Wellness Foundation Sweden, the Horizon 2020 Program (T2Dsystems), the Swedish Research Council (Dnr 2017-00862, Dnr 521-2012-2119, Linnaeus grant, Dnr 349-2006-237, and Strategic Research Area Exodiab, Dnr 2009-1039), the Swedish Foundation for Strategic Research (Dnr IRC15-0067) and ALF.